AIM AIM ImmunoTech Inc.
Price Chart
Executive Summary
AIM ImmunoTech announced an agreement with Thermo Fisher Scientific's PPD clinical research unit to design a Phase 3 trial for Ampligen in late-stage pancreatic cancer, based on promising Phase 2 DURIPANC trial data showing positive progression-free survival, overall survival, and safety signals. The move signals advancement toward late-stage development for a high-unmet-need indication, though no final efficacy data or regulatory approvals have been achieved yet.
Actionable Insight
Monitor for final Phase 2 data readout and formal initiation of the Phase 3 trial, which could serve as a catalyst; watch for financing activity given the company's small market cap and likely need for capital to fund late-stage trials.
Key Facts
- AIM ImmunoTech is partnering with Thermo Fisher Scientific’s PPD to design a Phase 3 trial for Ampligen in late-stage pancreatic cancer.
- The decision follows promising interim results from the ongoing Phase 2 DURIPANC trial, including Progression-Free Survival (PFS), Overall Survival (OS), and safety data.
- The Phase 2 trial is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands, enrolling up to 25 patients.
- AIM views pancreatic cancer as its highest-potential indication and has updated its corporate strategy accordingly.
- No final clinical results, efficacy endpoints, or regulatory approvals have been announced; the program remains in development.
Financial Impact
Potential long-term value if Phase 3 succeeds, but no near-term financial impact; significant future funding likely required
Risk Factors
- Phase 2 data is preliminary and based on a small, single-center study with only up to 25 subjects.
- No guarantee that Phase 3 trial will be initiated, funded, or successful.
- High risk of dilution given AIM's $4M market cap and capital-intensive nature of Phase 3 development.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $0.4543 awaiting T+1 | awaiting T+1 | — | $0.4100 (+9.75%) |
|
Jun 10, 2026
4d ago
|
424B5
| $0.4477 awaiting T+1 | awaiting T+1 | — | $0.4100 (+8.42%) |
|
Jun 8, 2026
6d ago
|
Press Release
| $0.4589 awaiting T+1 | awaiting T+1 | — | $0.4100 (−10.66%) |
|
Jun 4, 2026
10d ago
|
8-K
| $0.5900 $0.5200 | ▼ −11.86% | ▼ −9.27% | $0.4100 (−30.51%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $0.9000 $0.8300 | ▼ −7.78% | ▼ −7.92% | $0.4100 (−54.44%) |
|
May 21, 2026
24d ago
|
8-K
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.4100 (−70.83%) |
|
May 21, 2026
24d ago
|
424B5
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.4100 (−70.83%) |
|
May 20, 2026
25d ago
|
Press Release
| $0.2500 $0.2400 | ▲ +4.00% | ▲ +4.19% | $0.4100 (−64.00%) |
|
May 19, 2026
26d ago
|
424B5
| $0.2500 $0.2400 | ▼ −4.00% | ▼ −4.19% | $0.4100 (+64.00%) |
|
May 19, 2026
26d ago
|
8-K
| $0.4100 $0.2500 | ▼ −39.02% | ▼ −40.06% | $0.4100 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access